Strategy and validation of a structure-based method for the discovery of selective inhibitors of PAK isoforms and the evaluation of their anti-cancer activity
- 1 October 2019
- journal article
- research article
- Published by Elsevier in Bioorganic Chemistry
- Vol. 91, 103168
Abstract
No abstract availableKeywords
Funding Information
- Natural Science Foundation of Liaoning Province (20170540854)
This publication has 33 references indexed in Scilit:
- Tumor P-Glycoprotein Correlates with Efficacy of PF-3758309 in in vitro and in vivo Models of Colorectal CancerFrontiers in Pharmacology, 2013
- LCH-7749944, a novel and potent p21-activated kinase 4 inhibitor, suppresses proliferation and invasion in human gastric cancer cellsCancer Letters, 2012
- Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growthProceedings of the National Academy of Sciences, 2010
- Pharmacophore identification of PAK4 inhibitorsMolecular Simulation, 2010
- PAK signaling in oncogenesisOncogene, 2009
- The Pak4 Protein Kinase Plays a Key Role in Cell Survival and Tumorigenesis in Athymic MiceMolecular Cancer Research, 2008
- Death Receptor-Induced Activation of Initiator Caspase 8 Is Antagonized by Serine/Threonine Kinase PAK4Molecular and Cellular Biology, 2003
- Requirement for PAK4 in the Anchorage-independent Growth of Human Cancer Cell LinesJournal of Biological Chemistry, 2002
- A brain serine/threonine protein kinase activated by Cdc42 and Rac1Nature, 1994
- The avidin-biotin complex in immunologyImmunology Today, 1984